Expressing a stabilized form of β-catenin extends the lifespan of regulatory T cells— one goal of therapies that take advantage of these cells (pages 162–169).
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Katie Ris-Vicari
References
Tang, Q. & Bluestone, J.A. Immunol. Rev. 212, 217–237 (2006).
Ding, Y. Shen S., Lino, A.C., de Lafaille, M.A.C. & Lafaille, J.J. Nat. Med. 14, 162–169 (2008).
Clevers, H. Cell 127, 469–480 (2006).
Chao, D.T. & Korsmeyer, S.J. Annu. Rev. Immunol. 16, 395–419 (1998).
Diehn, M. et al. Proc. Natl. Acad. Sci. USA 99, 11796–11801 (2002).
Barker, N. & Clevers, H. Nat. Rev. Drug Discov. 5, 997–1014 (2006).
Willert, K. et al. Nature 423, 448–452 (2003).
Weerkamp, F., van Dongen, J.J. & Staal, F.J. Leukemia 20, 1197–1205 (2006).
Sansom, O.J. et al. Nature 446, 676–679 (2007).
Staal, F.J. & Clevers, H.C. Nat. Rev. Immunol. 5, 21–30 (2005).
Yu, Q., Xu, M. & Sen, J.M. J. Immunol. 179, 126–131 (2007).
Sakaguchi, S. Nat. Immunol. 6, 345–352 (2005).
Gavin, M.A. et al. Nature 445, 771–775 (2007).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bluestone, J., Hebrok, M. Safer, longer-lasting regulatory T cells with β-catenin. Nat Med 14, 118–119 (2008). https://doi.org/10.1038/nm0208-118
Issue Date:
DOI: https://doi.org/10.1038/nm0208-118
